Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64042056 in Preclinical Alzheimer’s Disease
2023-505096-68-00Phase 2Suspended
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing JNJ-64042056 with Placebo (2 arms). Primary endpoint: Change from baseline in brain tau burden. Started Oct 2024; status: suspended.
02
Drugs
ACI-35
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-505096-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505096-68-00.